Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has worked conscientiously but unsuccessfully to produce a single therapy, variously called Pro 140, leronlimab, along with Vyrologix.

In development of this particular therapy, CytoDyn has cast its net wide and far both geographically and in phrases of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will ever be being used is an open question.

While CYDY  is actually dawdling, market opportunities for leronlimab as being a combination therapy in the therapy of multi-drug-resistant HIV are actually closing.

I’m writing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale of my last several shares. My first CytoDyn article, “CytoDyn: What to be able to Do When It is Too Good To Be True?”, set out what follows prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan offered such a highly promotional image in the Uptick Newswire employment interview which I came away with an inadequate impression of the company.

Irony of irony, my poor opinion of the business has grown steadily, yet the disappointment hasn’t been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > 6 bagger at the moment still disappoints? Therein lies the story; let me explain.

CytoDyn acquired its much storied therapy (which I shall refer to as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for the therapy and avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity of HIV- infected subjects. Today’s payment of $3.5 huge number of transfers ownership of this technology and also linked intellectual property coming from Progenics to CytoDyn, and also approximately twenty five million mg of majority drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 huge number of) and also the first brand new drug application approval ($5 million), as well as royalty payments of five percent of net sales after commercialization.

Since that moment, CytoDyn’s leading nous, Nader Pourhassan [NP] has made this inauspicious acquisition into a springboard for CytoDyn to get a market place cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with multiple therapies and multiple indications, it has this individual therapies in addition to a “broad pipeline of indications” as it places it. I call some pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a potentially advantageous therapy in dozens of indications.

The opening banner of its on the website of its (below) shows an energetic company with diverse interests albeit focused on leronlimab, several illness sorts, multiple publications in addition to multiple presentations.

Can it all be smoke cigarettes and mirrors? That is a question I have been asking myself with the very beginning of my interest in this business. Judging by the multiples of a huge number of several remarks on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I’m far from alone in this particular question.

CytoDyn is a classic battleground, or maybe some could say cult inventory. Its adherents are fiercely shielding of the prospects of its, quick to label any negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *